Vertex scientists awarded the 2025 lasker~debakey clinical medical research award for pioneering discoveries in cystic fibrosis

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced that senior vice president paul negulescu has been named as one of the winners of this year's lasker~debakey clinical medical research award for his role “in the development of a novel, life-saving treatment for cystic fibrosis (cf) — namely, a triple-drug combination therapy, trikafta®, that has helped countless people with this genetic disease.” dr. negulescu is one of three awardees, alongside jesÚs (.
VRTX Ratings Summary
VRTX Quant Ranking